VivoSeq
Other

Myelokathexis

2

Pipeline Programs↗

0

Active Trials↗

2

Companies Involved↗

Myelokathexis is an early-stage landscape with 2 programs across 2 companies. The most active players are Genzyme, a Sanofi Company, Arog Pharmaceuticals, Inc..

Intelligence

Pipeline Metrics

Competitive Density

16/100

Pipeline Velocity

0/100

Mech. Concentration

100/100

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

G

Genzyme, a Sanofi Company

1 program

PreclinicalA

Arog Pharmaceuticals, Inc.

1 program

Preclinical

Pipeline

Programs by Phase

Preclinical2

Plerixafor

Genzyme, a Sanofi Company

G-CSF

Arog Pharmaceuticals, Inc.

Phase 1
No programs
Phase 2
No programs
Phase 3
No programs
Approved
No programs

Analysis

Trial Status

1

clinical trials

Completed1 · 100%

Clinical Trials

Trial Activity

A Phase III Double-Blind Randomized Crossover Study of Plerixafor Versus G-CSF in the Treatment of Patients With WHIM Syndrome.
Completed·National Institute of Allergy and Infectious Diseases (NIAID)·Preclinical·NCT02231879·20 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)